Systematic review of clinical trials of treatments for osteoarthritis in dogs

Journal of the American Veterinary Medical Association

Volumn 230, Issue 4, 2007, Pages 514-521

  Aragon, Carlos L ^a,b   Hofmeister, Erik H ^a   Budsberg, Steven C ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b MedVet Associates Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN; GLUCOSAMINE; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; DOG; DOG DISEASE; EVIDENCE BASED MEDICINE; HOSPITALIZATION; OSTEOARTHRITIS; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHONDROITIN; CLINICAL TRIALS; DOG DISEASES; DOGS; EVIDENCE-BASED MEDICINE; GLUCOSAMINE; OSTEOARTHRITIS; SEVERITY OF ILLNESS INDEX; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 33847793467     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.230.4.514     Document Type: Review

References (39)

1. Johnson SA. Osteoarthritis: joint anatomy, physiology, andpathobiology. Vet Clin North Am Small Anim Pract 1997;27:699-723.
2. Roush JK, McLaughlin RM, Radlinsky MG. Understanding the pathophysiology of Osteoarthritis. Vet Med 2002;97:108-117.
3. McLaughlin RM. Management of chronic osteoarthritic pain. Vet Clin North Am Small Anim Pract 2000;30:933-949.
4. Budsberg SC. Outcome assessment in clinical trials involving medical management of osteoarthritis in small animals. Vet Clin North Am Small Anim Pract 1997;27:815-823.
5. Lequesne M, Altman R, Bellamy N, et al. Guidelines for testing slow acting drugs in OA (SASOA). J Rheumatol 1994;21:65-71.
6. Moreau M, Dupuis J, Bonneau NH, et al. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec 2003;152:323-329.
7. Peterson KD, Keefe TJ. Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs. J Am Vet Med Assoc 2004;225:1056-1060.
8. Doig PA, Purbrick KA, Hare JE, et al. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J 2000;41:296-300.
9. Nell T, Bergman J, Hoeijmakers M, et al. Comparison of vedaprofen and meloxicam in dogs with musculoskeletal pain and inflammation. J Small Anim Pract 2002;43:208-212.
10. Lipscomb VJ, AliAbadi FS, Lees P, et al. Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis. Vet Rec 2002;150:684-689.
11. Schneider TA, Budsberg SC. Plasma and synovial concentrations of carprofen in dogs with chronic osteoarthritis. Vet Comp Orthop Traumatol 2001;14:19-24.
12. ™) in 209 clinical cases of canine degenerative joint disease. Vet Comp Orthop Traumatol 1992;5:140-144.
13. Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995;206:807-811.
14. Budsberg SC, Johnston SA, Schwarz PD, et al. Efficacy of elodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 1999;214:206-210.
15. Innes JF, Barr RS, Sharif BM. Efficacy of oral calcium pentosan polysulphate for the treatment of osteoarthritis of the canine stifle joint secondary to cranial cruciate ligament deficiency. Vet Rec 2000;146:433-437.
16. Read RA, Cullis-Hill D, Jones MP. Systemic use of pentosan polysulphate in the treatment of osteoarthritis. J Small Anim Pract 1996;37:108-114.
17. Bui LM, Bierer TL. Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther 2003;4:397-407.
18. Bierer TL, Bui LM. Improvement of arthritic signs in dogs fed green-lipped mussel (Perna canaliculus). Am Soc Nutr Sci 2002;132:16345-16365.
19. de Haan JJ, Goring RL, Beale BS. Evaluation of polysulfated glycosaminoglycan for the treatment of hip dysplasia in dogs. Vet Surg 1994;23:177-181.
20. Brandt KD, Smith GN, Myers SL. Hyaluronan injection affects neither osteoarthritis progression nor loading of the OA knee in dogs. Biorheology 2004;41:493-502.
21. Innes JF, Fuller CJ, Grover ER, et al. Randomised, double-blind, placebo-controlled parallel group study of P54FP for the treatment of dogs with osteoarthritis. Vet Rec 2003;152:457-460.
22. Boothe DM. Nutraceuticals in veterinary medicine. Part II. Safety and efficacy. Campend Contin Educ Pract Vet 1998;20:15-21.
23. US FDA Web site. Interim evidence-based ranking system for scientific data. Available at: www.cfsan.fda.gov/~dms/hclmgui4.html. Accessed May 16, 2005.
24. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116-128.
25. Aragon CL, Budsberg SC. Applications of evidence-based medicine: cranial cruciate ligament injury repair in the dog. Vet Surg 2005;34:93-98.
26. Forsyth SF, Guilford WG, Haslett SJ, et al. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract 1998;39:421-424.
27. Fox SM, Johnson SA. Use of carprofen for the treatment of pain and inflammation in dogs. J Am Vet Med Assoc 1997;210:1493-1498.
28. Jenkins CC, Kanara EW. First-year clinical experience with Rimadyl (carprofen): assessment of product safety. Pfizer Animal Health Technical Bulletin, May 1998.
29. Fox SM, Campbell S. Update: two years (1997-1998) clinical experience with Rimadyl (carprofen). Pfizer Animal Health Technical Bulletin, August 1999.
30. MacPhail CM, Lappin MR, Meyer DJ, et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998;212:1895-1901.
31. Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum 1999;28:211-267.
32. Francis DJ, Hutadilok N, Kongtawelert P, et al. Pentosan polysulphate and glycosaminoglycan polysulphate stimulates the synthesis of hyaluronan in vivo. Rheumatol Int 1993;13:61-64.
33. Golding JC, Ghosh P. Drugs for osteoarthritis. The effects of pentosan polysulfate (SP54) on the degradation and loss of proteoglycans from articular cartilage in a model of osteoarthrosis induced in the rabbit knee joint by immobilation. Curr Ther Res Clin Exp 1983;33:173-184.
34. Ammon HPT, Wahl MA. Pharmacology of curcuma-longa. Planta Medica 1991;57:1-7.
35. Miquel J, Bernd A, Sempere JM, et al. The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 2002;34:37-46.
36. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1998.
37. Levine M, Ensom MHH. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy 2001;21:405-409.
38. Maggard MA, O'Connel JB, Liu JH, et al. Sample size calculations in surgery: are they done correctly? Surgery 2003;134:275-279.
39. Freedman KB, Back S, Bernstein J. Sample size and statistical power of randomized, controlled trials in orthopedics. J Bone Joint Surg Br 2001;83-B:397-402.